9 completed, 3 terminated, 1 not yet recruiting, 1 unknown. 7 Phase 2, 6 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 6 | Completed 4, Not yet recruiting 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow Adjuvant: new trials by email Literature Review of Adjuvant trials Research Report on Adjuvant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TVAX-028 in the Treatment of Chronic Hepatitis B TVAX-028, Adjuvant - HBV Infection | Phase 1 | Not yet recruiting | Grand Theravac Life Sciences (Nanjing) Co., Ltd. | 32 | 2026-05-31 | 2026-06-29 |
| Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab Pembrolizumab, Pembrolizumab and Olaparib, Pembrolizumab adjuvant - Cancer | Phase 2 | Withdrawn | Gustave Roussy, Cancer Campus, Grand Paris | 2025-01-01 | 2025-12-01 | |
| Evaluation of Adjuvant Use in Selective Trunk Block Dexamethasone, kontrol group - Analgesia, Nerve Blocks | Not applicable | Completed | Gaziosmanpasa Research and Education Hospital | 71 | 2023-04-28 | 2024-09-24 |
| Predictive Assay for Decision Making in Adjuvant Therapy Adjuvant, Observation - Carcinoma, Non-Small-Cell Lung | Terminated | Insight Molecular Diagnostics | 55 | 2022-01-28 | 2022-11-14 | |
| The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults SCTV01C, Adjuvant, Saline - COVID-19 | Phase 1 / Phase 2 | Completed | Sinocelltech Ltd. | 478 | 2021-12-01 | 2024-02-08 |
| A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma NEO-PV-01, Nivolumab, Adjuvant - Metastatic Melanoma | Phase 1 | Terminated | BioNTech US Inc. | 22 | 2018-10-08 | 2020-09-03 |
| A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer NEO-PV-01, Pembrolizumab, Adjuvant - Carcinoma, Non-Small-Cell Lung, Lung Cancer | Phase 1 | Completed | BioNTech US Inc. | 38 | 2018-05-04 | 2021-02-26 |
| Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection GEN-003, Matrix-M2, 0.9% normal saline - Genital Herpes, HSV-2 Infection | Phase 2 | Terminated | Genocea Biosciences, Inc. | 33 | 2017-05-24 | 2019-02-19 |
| A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer NEO-PV-01, Nivolumab, Adjuvant - Urinary Bladder Cancer, Bladder Tumors | Phase 1 | Completed | BioNTech US Inc. | 34 | 2016-10-01 | 2021-02-25 |
| Novel Mechanisms and Approaches to Treat Neonatal Sepsis Adjuvant, Blood Collection - Complication of Prematurity, Immunologic Deficiency Syndromes | Completed | University of Florida | 142 | 2016-02-01 | 2023-02-10 | |
| Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL TVGV-1, GPI-0100, Placebo - Human Papillomavirus, High-Grade Squamous Intraepithelial Lesions | Phase 2 | Unknown | THEVAX Genetics Vaccine | 10 | 2015-11-01 | 2017-10-25 |
| Evaluating New Formulation of Therapeutic HSV-2 Vaccine Matrix-M2, GEN-003, Placebo - Genital Herpes Simplex Type 2 | Phase 2 | Completed | Genocea Biosciences, Inc. | 131 | 2015-11-01 | 2018-05-22 |
| Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg) - Genital Herpes Simplex Type 2 | Phase 2 | Completed | Genocea Biosciences, Inc. | 37 | 2015-01-01 | 2017-10-16 |
| Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg) - Genital Herpes Simplex Type 2 | Phase 2 | Completed | Genocea Biosciences, Inc. | 310 | 2014-07-01 | 2017-10-16 |
| Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant Fluzone vaccine with JVRS-100 adjuvant, Fluzone vaccine - Influenza | Phase 1 | Completed | Colby Pharmaceutical Company | 128 | 2008-06-01 | 2010-03-17 |
Herpes Simplex (4) · Carcinoma, Non-Small-Cell Lung (3) · Herpes Genitalis (2) · Lung Neoplasms (2) · Melanoma (2) · Agnosia (1) · COVID-19 (1) · Immunologic Deficiency Syndromes (1) · Influenza, Human (1) · Liposarcoma (1) · Neoplasms (1) · Pain, Postoperative (1) · Sarcoma (1) · Skin Neoplasms (1) · Squamous Intraepithelial Lesions (1)
Genocea Biosciences, Inc. (4) · BioNTech US Inc. (3) · Colby Pharmaceutical Company (1) · Gaziosmanpasa Research and Education Hospital (1) · Grand Theravac Life Sciences (Nanjing) Co., Ltd. (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Insight Molecular Diagnostics (1) · Sinocelltech Ltd. (1) · THEVAX Genetics Vaccine (1) · University of Florida (1)
United States (11) · China (1) · France (1) · Turkey (Türkiye) (1)
Mark DeMario, MD (3) · Corey Langer, MD (1) · Frank L Douglas, PhD, MD (1) · Shawn Larson, MD (1) · Thomas P Monath, MD (1) · Yimin Cui, M.D. (1)
PMID 31103365, PMID 32955177, PMID 33064988, PMID 33294862, PMID 35950709, PMID 36403700, PMID 39834144
R01GM097531 (1)